X
Upload your Marketing & Sales content on your company Virtual Booth, click HERE.
Details:
EasyFourPol is the world's first fully-liquid wP-IPV based Pentavalent vaccine, which is launched in India to protect children against five deadly diseases: Diphtheria, Tetanus, Pertussis, Polio, and invasive infections caused by Haemophilus Influenza Type b.
Lead Product(s): Hib DTP Poliovirus Vaccine
Therapeutic Area: Infections and Infectious Diseases Product Name: EasyFourPol
Highest Development Status: ApprovedProduct Type: Vaccine
Partner/Sponsor/Collaborator: Not Applicable
Deal Size: Not Applicable Upfront Cash: Not Applicable
Deal Type: Not Applicable December 17, 2023
Details:
The top selling brands are Pangraf (tacrolimus), Alphadol (alfacalcidol), Cilamin (penicillamine) & Livoluk Fibre (lactulose in combination with ispaghula) were ranked number 1, whereas Glizid (Gliclazide + Metformin), Mycept (Mycophenolate Mofetil) were among the top 5.
Lead Product(s): Tacrolimus
Therapeutic Area: Dermatology Product Name: Pangraf
Highest Development Status: ApprovedProduct Type: Small molecule
Recipient: Mankind Pharma
Deal Size: $251.1 million Upfront Cash: Undisclosed
Deal Type: Agreement February 01, 2022
Details:
DengiAll, a single-dose live-attenuated tetravalent vaccine induced robust, balanced neutralizing antibody responses against all four Dengue virus serotypes. After single-dose, more than 80% of participants showed Tri-valent response and ~95% showed multivalent response.
Lead Product(s): Tetravalent Recombinant Chimeric Dengue Vaccine
Therapeutic Area: Infections and Infectious Diseases Product Name: DengiAll
Highest Development Status: Phase I/ Phase IIProduct Type: Vaccine
Partner/Sponsor/Collaborator: Not Applicable
Deal Size: Not Applicable Upfront Cash: Not Applicable
Deal Type: Not Applicable September 30, 2021
Details:
Patient recruitment and dosing is ongoing in Nuvation Bio’s Phase 1/2 study of its lead investigational compound, NUV-422, a CDK2/4/6 inhibitor, in patients with high-grade gliomas, including glioblastoma multiforme (GBM).
Lead Product(s): NUV-422
Therapeutic Area: Oncology Product Name: NUV-422
Highest Development Status: Phase I/ Phase IIProduct Type: Small molecule
Recipient: Nuvation Bio
Deal Size: $830.0 million Upfront Cash: Undisclosed
Deal Type: Merger February 10, 2021
Details:
DengiAll has illustrated the strength of Panacea Biotec’s expertise in vaccinology, research, development, and manufacturing while leveraging NIH’s ability to work on complex biological challenges to develop breakthrough technologies.
Lead Product(s): Tetravalent recombinant chimeric Dengue vaccine
Therapeutic Area: Infections and Infectious Diseases Product Name: DengiAll
Highest Development Status: Phase I/ Phase IIProduct Type: Vaccine
Partner/Sponsor/Collaborator: Not Applicable
Deal Size: Not Applicable Upfront Cash: Not Applicable
Deal Type: Not Applicable September 24, 2020
Details:
Panacea Biotec has set production targets of 500 million doses for 2021 and one billion doses in 2022 for its COVID-19 vaccine candidate.
Lead Product(s): Covid-19 vaccine
Therapeutic Area: Infections and Infectious Diseases Product Name: Undisclosed
Highest Development Status: PreclinicalProduct Type: Vaccine
Partner/Sponsor/Collaborator: Not Applicable
Deal Size: Not Applicable Upfront Cash: Not Applicable
Deal Type: Not Applicable July 08, 2020
Details:
Under the collaboration, Panacea Biotec will be responsible for product development and commercial manufacturing, with the Joint Venture undertaking clinical development and regulatory submissions across the World.
Lead Product(s): Covid-19 vaccine
Therapeutic Area: Infections and Infectious Diseases Product Name: Undisclosed
Highest Development Status: UndisclosedProduct Type: Vaccine
Partner/Sponsor/Collaborator: Refana
Deal Size: Undisclosed Upfront Cash: Undisclosed
Deal Type: Collaboration June 10, 2020
FULL SCREEN VIEW Click here to open all results in a new tab [this preview display 10 results] 
Market Place
